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Abstract
Importance
Postnatal dexamethasone is associated with reduction in bronchopulmonary dysplasia.
There remains, however, concern that its short-term benefits are accompanied by long-term
adverse effects e.g. poorer neurodevelopmental outcomes.
Objective
Our aim was to determine the effects of administration of postnatal dexamethasone on
respiratory and neurodevelopmental outcome at two years of age after adjusting for neona-
tal and infant risk factors.
Materials and methods
The study included 412 infants born at 23–28 weeks of gestation, 29% had received postna-
tal dexamethasone. Two outcomes were examined, respiratory hospital admissions in the
past 12 months and neurodevelopmental impairment. Logistic regression, adjusted for sex,
birthweight z-score, gestation, maternal smoking, oxygen dependency at 36 weeks, airleak,
patent ductus arteriosus, pulmonary haemorrhage, major ultrasound abnormality, mode of
ventilation and age at assessment, was undertaken.
Results
After adjustment, postnatal dexamethasone was associated with significantly increased pro-
portions of both respiratory hospital readmission: (0.35 vs 0.15, difference = 0.20; 95% CI:
0.08, 0.31) and neurodevelopmental impairment (0.59 vs 0.45, difference = 0.14; 95% CI:
0.02, 0.26).
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Conclusions
Postnatal dexamethasone use in extremely preterm infants is associated with increased
risks of respiratory hospital admissions and neurodevelopmental impairment. These associ-
ations were not explained by excess neonatal morbidities.
Introduction
Infants born prematurely usually require respiratory support which, although often essential
for survival, can lead to lung damage, prolonged oxygen dependency and chronic respiratory
morbidity. The administration of the corticosteroids can improve respiratory function and
allow earlier extubation. Systematic review of randomised trials demonstrated that the admin-
istration of steroids before seven days facilitated extubation and reduced bronchopulmonary
dysplasia (BPD) [1]. Delayed corticosteroid treatment, i.e. after seven days, was also associated
with reductions in failure to extubate and BPD [2]. Corticosteroids, however, are linked to
adverse neurological effects when given early [1, 3] or late [2] and linked to inhibited second-
ary septation [4].
The aim of this study was to use the neonatal and two-year follow-up data from the United
Kingdom Oscillation Study (UKOS) [5,6] to explore the relationship between the use of post-
natal dexamethasone and later outcomes. We wished to determine whether there was any asso-
ciation with long term respiratory morbidity, as indicated by respiratory hospital readmission
and if in the UKOS extremely, prematurely born cohort there was evidence of increased
abnormal neurological outcome, as had been previously reported [7,8]. Furthermore, we
investigated whether any late adverse effects observed were explained by other neonatal mor-
bidities and if they correlated with the number of courses received.
Methods
In the UKOS trial, 797 babies were randomised to either high frequency oscillatory ventilation
(HFOV) or conventional ventilation (CV) [5]. Five hundred and ninety-two infants survived
to hospital discharge; the 412 infants who were seen at two years of age formed this dataset
(Fig 1). The UKOS trial and follow-up were approved by the London South Thames Multicen-
tre Research Ethics Committee. Parents gave informed written consent for their infants to take
part.
The administration of postnatal dexamethasone was assessed as i) received postnatal dexa-
methasone yes/no, ii) the timing of the dexamethasone administration (7 days = Early/>7
days = Late) using the definitions from the Cochrane reviews [1,2], iii) the number of courses
received, and iv) the number of days of dexamethasone exposure (analysed in four groups: 0
days, 1–6 days, 7–12 days and>12 days). UKOS participating centres were surveyed and con-
firmed the postnatal steroid used was dexamethasone.
Respiratory outcome at age two was determined as any respiratory hospital admission in
the previous 12 months as reported by parents to the paediatrician in a structured interview
when their child was two years corrected age [6]. To determine whether a respiratory hospital
admission, as recalled by the parents, was a true reflection of respiratory morbidity we assessed
whether admissions were related to reported cough or wheeze or use of ‘chest’ medication as
recorded at the same time, two years of age. Neurological outcome at age two years corrected
was defined in the same way as in our main UKOS follow-up paper [6] as at least one
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abnormality in one of the following domains: neuro-motor, vision, hearing, communication
or other physical disabilities, such as cerebral palsy. No impairment was defined as ‘normal’, as
was a missing response to all of the above domains. This reflected clinical opinion as to the
meaning of ‘missing’ in this context. [6] These two outcomes, respiratory admissions and neu-
rodevelopmental impairment were chosen a priori as indicators of morbidity. No other analy-
ses were performed.
Analysis
In the primary analysis we used multivariable logistic regression to examine the effect of post-
natal dexamethasone on the above outcomes, adopting a similar analysis strategy to that we
have used in earlier work in the UKOS study [9] and in other research in the long-term effects
of postnatal dexamethasone [10]. The following neonatal factors were included as potential
associations of poor outcome at age two: infant sex, birthweight z-score, gestational age, mater-
nal smoking during pregnancy, oxygen dependency at 36 weeks postmenstrual age (PMA),
major cranial ultrasound abnormality, airleak, patent ductus arteriosus (PDA), pulmonary
haemorrhage and mode of ventilation. Age at the two year assessment was also included as a
potential confounder. The association between each postnatal dexamethasone measure and
each outcome was first analysed in the regression model without adjustment and then with
Fig 1. Study flow chart.
https://doi.org/10.1371/journal.pone.0181176.g001
Postnatal dexamethasone and age 2 outcomes
PLOS ONE | https://doi.org/10.1371/journal.pone.0181176 July 19, 2017 3 / 10
adjustment for confounders. In a sensitivity analysis, we adjusted for oxygen dependency at 28
days in place of oxygen dependency at 36 weeks PMA.
Since the use of postnatal dexamethasone is so highly confounded by neonatal factors, we
also used propensity score matching for dexamethasone exposure (yes/no) [11] as an alterna-
tive way of adjustment in addition to multivariable logistic regression. Propensity score (PS)
matching works differently to multiple logistic regression by matching the subjects as closely
as possible using baseline factors prior to analysis so that the study closely resembles a rando-
mised trial. The following baseline factors were used in the propensity score matching: sex,
birthweight, birthweight z-score, gestational age in weeks, smoking in pregnancy, multiple
birth, ventilation group and Apgar score. It is not recommended to adjust for non-baseline fac-
tors and so age at assessment was not used in the PS analysis. The main challenge of the PS
method is to obtain close matches for all subjects. It was not possible to use propensity score
matching for three measures of dexamethasone exposure, that is timing of administration,
number of courses and days of exposure due to the small numbers in the different dexametha-
sone-use categories. For this reason only adjustment by multivariable logistic regression was
undertaken for those measures. The effects of postnatal dexamethasone were calculated as
odds ratios but reported in the main text as the marginal proportions in the categories and dif-
ferences with 95% confidence interval to improve clinical interpretability. Results as odds
ratios are given in the supporting information (Tables A,B in S1 File). Marginal proportions
could not be calculated for the propensity score estimates and so the odds ratios for the pro-
pensity score analyses (OR) were converted to a difference in proportions (p1-p2) as follows:
using the observed proportion for the unexposed group (p1) then calculate the calculate the
proportion in the exposed group (p2) using the formula: p2 = p1/(OR-ORp1+p1).
Finally we computed the correlations between respiratory admissions and respiratory
symptoms and present these as odds ratios to validate the use of respiratory admissions as a
summary of poor respiratory outcome.
Each analysis used cases with complete data so that the numbers were the same for each
analysis. All statistical analyses were performed using the Stata 14 software.
Results
The baseline characteristics of those with and without complete data were similar apart from
oxygen dependency at 36 weeks postmenstrual age (PMA) which was commoner in those with
complete data, 58% vs 49% (Table 1). This was true in those with and without exposure to
postnatal dexamethasone: 82% vs 75% were oxygen dependent at 36 weeks PMA among those
exposed compared to 49% vs 39% in the unexposed. Oxygen dependency at 36 weeks PMA
was included in both the multivariable analyses and the propensity score matching.
One hundred and twenty out of 412 infants (29%) had received postnatal dexamethasone,
of those 63 (53%) received one course, 26% received two courses and the remainder received
three courses. The majority (93%) had received dexamethasone more than seven days after
their birth. Forty three percent of infants had received dexamethasone for more than 12 days,
37% for 7–12 days and the remainder for less than 7 days.
Eighty-eight (21%) of the infants had a respiratory hospital readmission between age one
and two years. Postnatal dexamethasone exposure was associated with a statistically significant
increased proportion of readmissions in the previous 12 months both before and after statisti-
cal adjustment (0.35 vs 0.15, Table 2). This is equivalent to a number needed to treat of 5. The
difference in proportions was reduced in size with propensity score matching, but it remained
statistically significant (difference = 0.03 (95% CI 0.01, 0.06), p = 0.005). The risk of hospital
admission was positively associated with increasing numbers of courses of dexamethasone and
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this remained significant after adjustment. Both early and late administration of dexametha-
sone was significantly associated with increased proportions of respiratory hospital admissions
in comparison to no exposure, both before and after adjustment. Additionally, the difference
in proportions was reduced in size for the late administration of dexamethasone in compari-
son to early (Table 2). Respiratory hospital admission was strongly associated with cough
(OR = 4.44; 95% CI: 2.60, 7.57), wheeze (5.15; 3.07, 8.64) and use of chest medication (10.38;
4.93, 21.83) at two years of age.
Overall 201 (49%) of the infants had some neurodevelopmental impairment at age two.
Postnatal dexamethasone exposure was associated with a significantly increased proportion of
any impairment before adjustment and, although the difference in proportions was reduced in
size after adjustment, it remained statistically significant (Table 3). This association was con-
firmed with the propensity score matching which also indicated a significantly increased pro-
portion of any impairment with postnatal dexamethasone exposure (difference = 0.07; 95%CI:
0.03,0.11, p< 0.001). The association between the number of courses of dexamethasone and
any impairment remained significant after adjustment while there was no clear association of
early administration of dexamethasone on impairment although numbers were small n = 9,
Table 3).
The final sensitivity analysis for the regression models: adjusted for oxygen dependency at
28 days in place of oxygen dependency at 36 weeks (Table C in S1 File) showed very similar
results to those described above. The results expressed as odds ratios are shown in tables A and
B of the supporting information document (Table A, B in S1 File).
Diagnostic investigation of the propensity score matching showed that all cases were
matched and that data from only two subjects were more than 0.025 apart from their match.
Sensitivity analysis excluding these two subjects made no appreciable difference to the esti-
mates. These results and the distribution of the propensity scores are shown in the supporting
information (Figure A, Text, Table A in S1 File).
Discussion
We have shown an association between exposure to early or late postnatal dexamethasone and
respiratory hospital readmission. This association was reduced but remained statistically
Table 1. Baseline characteristics of the infants included in this study and those not included, based on incomplete data for postnatal dexametha-
sone use and age 2 outcomes as defined.
Sample analysed with complete
data N = 412
Sample not analysed with
incomplete data N = 180
Comparison of complete and
incomplete samples
Characteristics % (n) or mean (SD) % (n) or mean (SD) p-value
Birth weight 899 (210) 907 (193) 0.66
Gestational age 26.4 (1.3) 26.4 (1.3) 0.88
Male sex 52% (216) 52% (93) 0.87
Multiple birth 23% (96) 19% (35) 0.30
Postnatal dexamethasone Use 29% (120) 30% (52) 0.85
Oxygen dependency at 28 days 81% (335) 77% (139) 0.25
Oxygen dependency at 36 weeks
PMA
58% (240) 49% (88) 0.04
Oxygen dependency at hospital
discharge
23% (93) 16% (29) 0.08
Major ultrasound abnormality in
neonatal period
14% (59) 13% (23) 0.63
Maternal smoking in pregnancy 25% (99) 33% (52) 0.07
https://doi.org/10.1371/journal.pone.0181176.t001
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significant after adjustment for neonatal and infant factors and was robust to adjustment using
two different statistical approaches. The proportion of infants who had had respiratory admis-
sions increased with the number of courses. The associations with respiratory admissions
remained statistically significant after adjustment using propensity score matching. We
observed strong correlations between reported respiratory admission and cough, wheeze and
use of chest medications, validating the use of respiratory admission as a marker of respiratory
morbidity.
The results of studies examining respiratory health in childhood after postnatal steroid
administration have been conflicting. In one series, children who had received postnatal
Table 2. Respiratory hospital admissions and postnatal dexamethasone exposure.
Respiratory hospital admission n = 88, 21%
N Unadjusted proportions Adjusted proportions 1
Dexamethasone exposure p-value<0.001
No 292 0.15 0.15
Yes 120 0.36 0.35
Difference (95% CI)
Yes vs no 0.20 (0.11, 0.30) 0.20 (0.08, 0.31)
Timing of dexamethasone Overall p-value:
<0.001
Overall p-value:
<0.001
None 292 0.15 0.15
Early 9 0.44 0.48
Late 111 0.35 0.34
Differences (95% CI)
Early vs none 0.29 (-0.04, 0.62) 0.33 (-0.01, 0.66)
Late vs none 0.20 (0.10, 0.30) 0.18 (0.07, 0.30)
No. of courses Overall p-value:
<0.001
Overall p-value:
0.001
0 course 292 0.15 0.15
1 course 76 0.34 0.33
2 courses 31 0.39 0.38
3 courses 13 0.38 0.40
Differences (95% CI)
1 vs 0 courses 0.19 (0.07, 0.30) 0.18 (0.06, 0.30)
2 vs 0 courses 0.23 (0.06, 0.41) 0.23 (0.03, 0.43)
3 vs 0 courses 0.23 (-0.04, 0.50) 0.25 (-0.05, 0.55)
No. of days of exposure Overall p-value:
<0.001
Overall p-value:
<0.001
0 292 0.15 0.15
1–6 24 0.21 0.22
7–12 44 0.41 0.39
>12 51 0.40 0.38
Differences (95% CI)
1–6 vs 0 0.05 (-0.11, 0.22) 0.07 (-0.10, 0.24)
7–12 vs 0 0.25 (0.10, 0.41) 0.23 (0.08, 0.39)
>12 vs 0 0.24 (0.10, 0.38) 0.23 (0.07, 0.39)
1
. Adjusted for sex, birthweight z-score, gestational age in weeks, smoking in pregnancy, oxygen dependency at 36 weeks, airleak, patent ductus
arteriosus, pulmonary haemorrhage, major neonatal ultrasound abnormality, ventilation group and age at 24 month assessment using multiple logistic
regression analysis.
https://doi.org/10.1371/journal.pone.0181176.t002
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corticosteroid had lower FEV1 (82 vs 88%, p = 0.006) and FEF25-75 (65% versus 78%,
p = 0.003). The mean cumulative dose of postnatal corticosteroid administration was 7.8 mg/
kg, but no dose effect on lung function was found [12]. In the largest follow-up study, Jones
[13] evaluated pulmonary function in 142 children aged 13 to 17 years who participated as
infants in the Collaborative Dexamethasone Trial [14], a multicentre postnatal randomized
controlled trial of one week of dexamethasone treatment. Even though beneficial effects of
dexamethasone were seen in the postnatal period (i.e. fewer days of ventilator dependence)
[15] no differences between the dexamethasone (n = 68) and placebo (n = 74) groups were
noted at follow-up in terms of FVC, FEV1, FEV1/FVC, FEF25-75, peak expiratory flow rate,
Table 3. Any neurodevelopmental impairment and postnatal dexamethasone exposure.
Any neurodevelopmental impairment n = 201 49%
N Unadjusted proportions Adjusted proportions 1
Dexamethasone exposure p-value<0.001
No 292 0.43 0.45
Yes 120 0.63 0.59
Difference (95% CI)
Yes vs no 0.19 (0.09, 0.30) 0.14 (0.02, 0.26)
Timing of dexamethasone Overall p-value:
<0.001
Overall p-value:
<0.001
None 292 0.43 0.45
Early 9 0.56 0.56
Late 111 0.63 0.59
Differences (95% CI)
Early vs none 0.12 (-0.21, 0.45) 0.11 (-0.22, 0.45)
Late vs none 0.20 (0.09, 0.31) 0.14 (0.02, 0.27)
No. of courses Overall p-value:
<0.001
Overall p-value:
0.001
0 course 292 0.43 0.45
1 course 76 0.62 0.59
2 courses 31 0.61 0.58
3 courses 13 0.69 0.57
Differences (95% CI)
1 vs 0 courses 0.19 (0.06, 0.31) 0.14 (0.01, 0.28)
2 vs 0 courses 0.18 (0.00, 0.36) 0.13 (-0.06, 0.32)
3 vs 0 courses 0.26 (0.00, 0.52) 0.12 (-0.21, 0.45)
No. of days of exposure Overall p-value:
<0.001
Overall p-value:
<0.001
0 292 0.43 0.45
1–6 24 0.75 0.70
7–12 44 0.50 0.45
>12 51 0.67 0.65
Differences (95% CI)
1–6 vs 0 0.32 (0.14, 0.50) 0.25 (0.06, 0.45)
7–12 vs 0 0.07 (-0.09, 0.23) 0.00 (-0.18, 0.18)
>12 vs 0 0.24 (0.09, 0.38) 0.21 (0.05, 0.37)
1
. Adjusted for sex, birthweight z-score, gestational age in weeks, maternal smoking in pregnancy, oxygen dependency at 36 weeks PMA, airleak, patent
ductus arteriosus, pulmonary haemorrhage, major neonatal ultrasound abnormality, ventilation group and age at 24 month assessment using multiple
logistic regression analysis.
https://doi.org/10.1371/journal.pone.0181176.t003
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bronchodilator responsiveness, or respiratory morbidity (ie, current asthma, wheezing, cough-
ing, inhaler use). It is important to note that a large proportion of the placebo group (39%)
were exposed to open-label dexamethasone which may have attenuated possible treatment
effects. A study pulmonary function at 15 years of age was significantly better for children who
had received a 42 day course of postnatal dexamethasone compared to an 18 day course
(FEV1, 90% versus 71%) and there was no significant difference in the lung function of the 42
day group and the controls [16]. In that study, the children who received a 42 day course had a
sustained improvement in respiratory health and neurodevelopment, whereas those receiving
the 18 day course after an initial improvement required increased respiratory support once the
steroids were discontinued. Another study [17] demonstrated less dexamethasone treated
infants at 8–11 years of age had an FEV1 below normal (40% versus 68%, p = 0.03), but parent
reported prevalence of asthma did not differ between the two groups. Logistic regression anal-
ysis suggested the positive effects of dexamethasone were mediated in part by a shortened post-
natal exposure to mechanical ventilation. The infants had received a 42 day tapering course of
steroids [17]. Mieskonen et al also showed a beneficial effect of postnatal dexamethasone but
their sample size was small, eight were treated with a week long course of dexamethasone and
eight given placebo. They found a significantly higher FVC in 7–9 year old children but no dif-
ferences in forced expiratory flow rate [18]. Of all the above studies, only the subjects of Smith
et al [12] were born in the post-surfactant era and were generally born more prematurely than
the participants in the other studies. Their population [12] then are the most similar to our
own, both studies demonstrated in infants routinely exposed to antenatal steroids and postna-
tal surfactant, postnatal steroids were associated with worse long term respiratory outcomes.
This follow-up study in infants born extremely prematurely has shown an association
between both early and late administration of postnatal dexamethasone and poor neurodeve-
lopmental outcome at age two years. This association was reduced in strength but remained
statistically significant after adjustment for neonatal and infant factors and as with respiratory
admission, the association remained significant after adjustment using two different statistical
approaches. Dexamethasone has been associated with altered maturation of neurones in pre-
term infants which may account for the adverse neurodevelopmental effects of postnatal treat-
ment [7]. Other possible mechanisms for reduced brain growth associated with postnatal
dexamethasone include inhibition of growth factors and facilitation of apoptosis [7]. In a pre-
vious study [10] neurodevelopmental impairment was also increased with increasing dose of
dexamethasone, but not postnatal age.
This study has strengths and some limitations. The data were from a randomised trial [5];
there were no significant differences shown in the short term outcomes [6] and adjusting for
the intervention group did not affect the results presented in this paper. The baseline charac-
teristics in those with and without complete data were similar apart from oxygen dependency
at 36 weeks postmenstrual age which was commoner in those with complete data. This is con-
sistent with our previous observations that children with missing data and those who dropped
out tend to have fewer health problems. This observation held in both those with and without
exposure to postnatal dexamethasone. This was included in the multivariable analyses and the
propensity score matching. Further, sensitivity analyses using 28-day oxygen dependency
showed similar results and so overall we do not consider that this has biased the results pre-
sented here.
In conclusion, our data provide evidence that in extremely premature infants, the use of
postnatal dexamethasone is associated with an increased risk of respiratory morbidity and
neurodevelopmental impairment at follow up. These associations were not explained by a
higher proportion of infants with neonatal morbidities in the dexamethasone group. In
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addition, the risk of respiratory related hospital admission was increased by increasing num-
bers of postnatal dexamethasone courses.
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